Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Neuroblastoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

CNS Tumor (591)

Brain Cancer (583)

Pituitary Gland Carcinoma (10)

CNS Tumor (591)

Brain Cancer (583)

Pituitary Gland Carcinoma (10)

›

No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	dinutuximab beta Sensitive: A1 - Approval dinutuximab beta Sensitive : A1	dinutuximab beta Sensitive: A1 - Approval dinutuximab beta Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	melphalan Sensitive: A1 - Approval melphalan Sensitive : A1	melphalan Sensitive: A1 - Approval melphalan Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	dinutuximab Sensitive: A1 - Approval dinutuximab Sensitive : A1	dinutuximab Sensitive: A1 - Approval dinutuximab Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	naxitamab-gqgk Sensitive: A1 - Approval naxitamab-gqgk Sensitive : A1	naxitamab-gqgk Sensitive: A1 - Approval naxitamab-gqgk Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	eflornithine Sensitive: A1 - Approval eflornithine Sensitive : A1	eflornithine Sensitive: A1 - Approval eflornithine Sensitive : A1
ALK positive	Neuroblastoma	ALK positive	Neuroblastoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ALK positive	Neuroblastoma	ALK positive	Neuroblastoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ALK R1275Q	Neuroblastoma	ALK R1275Q	Neuroblastoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ATRX mutation	Neuroblastoma	ATRX mutation	Neuroblastoma	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3